Navigation Links
U.S. Biomedical Leaders Present a New National Device Innovation Strategy Based on "Value-driven Engineering"
Date:6/16/2011

itiveness: innovation and manufacturing," he said. "The national strategy released today will lead to the creation of jobs in Ohio and across the country while ensuring that the United States maintains an edge in the growing biomedical industry. Thanks to the remarkable work of Dr. Frank Douglas and the many stakeholders involved, the ABIA is leading the nation in advancing the American biomedical industry. Akron is once again on the map as a world leader in innovation, collaboration, and commercialization. I look forward to hearing of the Institute's continued progress and success."

"Part of our success in industry relies on our ability to meet patient needs while providing a useful product that is safe, efficient and cost-effective enough for purchasers to invest in," said Mike Hess, Vice President of Innovation Excellence at Medtronic. "We believe the adoption of these principles from all involved – whether they be in industry, academia, venture philanthropy or the public sector – will help to spur innovation in the biomedical sector."

"A common theme throughout this effort is ensuring innovators are supported through all stages of their development – from classroom to the commercialization of innovations," said Dr. Youseph Yazdi, Executive Director, Center for Bioengineering Innovation and Design, Johns Hopkins University.  "In order to produce value-driven engineers, we must create educational environments in which our students practice Value-driven Engineering in a practical sense. In the white paper, we introduce a series of recommendations for increasing education around Value-driven Engineering focused on the development of critical partners, leveraging federal funding strategies and promoting workforce development."

The national Safe Haven Summit that ABIA convened in Washington, D.C., in March, included participation by a number of industry leading organizations such as the Cleveland Clinic, Johns Hopkins Univer
'/>"/>

SOURCE Austen BioInnovation Institute in Akron
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. Top Latin-American scientists named 2011 Pew Fellows in the Biomedical Sciences
2. 22 of Americas most promising scientists selected as 2011 Pew Scholars in the Biomedical Sciences
3. Stevens biomedical engineering students fight hypothermia on the battlefield
4. Tufts biomedical engineer Fiorenzo Omenetto named Guggenheim Fellow
5. Brigham and Womens Hospital researcher named National Space Biomedical Research Institute Fellow
6. Vilcek Foundation names recipients of 2011 Vilcek Prizes in Biomedical Science
7. JAMA features NJIT biomedical engineer helping stroke patients
8. Tufts announces public launch of the Tufts Institute for Biomedical Partnerships website/HUB
9. President Obama calls for increased investment in science, including biomedical research
10. Finland initiates European biomedical research infrastructures construction with $6.7 million for 2011
11. Biomedical breakthrough: Blood vessels for lab-grown tissues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. ... molecular diagnostics, today announced the launch of a ... Company,s Precision Cancer Monitoring℠ (PCM) technology for predicting ... one or a combination of the novel immunotherapy ... (nivolumab), a PD-1 inhibitor. The 50-patient study will ...
(Date:7/7/2015)... , June 30, 2015 ... announced the addition of the "Capacitive Fingerprint ... To this date, fingerprint sensing technology ... and fingerprint sensors are well developed. This patent ... technology. The domain of capacitive fingerprint ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... Bucknell University biology professor Chris Martine has discovered and ... Lost City. Martine, who named the plant Solanum cowiei ... PhytoKeys . Martine described the plant as "gender ... male by producing pollen. "What they,re really doing ...
... Current pledges for greenhouse gas emission reductions are ... reach internationally agreed climate targets, according to new ... research teams coordinated by the International Institute for ... for Climate Impacts Research (PIK)., In the absence ...
... alcohol severely disrupts major features of brain development ... motor function, conditions typical in humans with Fetal ... the University of California, Riverside. In a ... prenatal exposure to alcohol significantly altered the expression ...
Cached Biology News:Unlikely collaboration leads to discovery of 'gender-bending' plant 2Unlikely collaboration leads to discovery of 'gender-bending' plant 3Continuing with pledge pathways to 2030 could push climate goals out of reach 2Prenatal exposure to alcohol disrupts brain circuitry 2Prenatal exposure to alcohol disrupts brain circuitry 3
(Date:7/30/2015)... 2015   GenoSpace , a leading provider ... analysis of genomic and other biomedical data, today ... the company as Vice President of Sales and ... "GenoSpace partners with its customers ... and explore complex sets of genomic, phenotypic and ...
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
(Date:7/30/2015)...   Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... results for the second quarter 2015. ... on track to achieve our commercial and financial goals," ... the Company. "Since our last quarterly earnings report, our ...
(Date:7/30/2015)... -- HIGHLIGHTS:Q2 2015 Results (all changes are ... sales were $697 million compared to $701 million in ... 8%, and changes in foreign currency exchange rates decreased ... , By business unit, organic sales growth was ... SAFC Commercial. , Reported diluted EPS was $0.98 ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... ITMN ) today announced that five abstracts from clinical ... programs related to the hepatitis C virus (HCV) have been ... European Association for the Study of the Liver (EASL, April ... to be available at www.easl.ch . ITMN-191 is ...
... David P. Wright, Co-Chair of the Alliance ... Inc., testified today before the House Labor, Health ... the critical importance of developing drugs, vaccines and ... bioterrorism and other catastrophic health emergencies. Effective medical ...
... BBK Worldwide to Better Serve Asia-Pacific Clinical Trial ... a global leader in patient recruitment for clinical ... -- Osaka, G.K., in Osaka, Japan. The company ... and medical device companies, as well as CROs ...
Cached Biology Technology:InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting 2InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting 3Alliance for Biosecurity Testifies Before Congress on Funding for Medical Countermeasure Development 2Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace 2Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace 3
Rabbit polyclonal to MAL ( Abpromise for all tested applications). entrezGeneID: 4118 SwissProtID: P21145...
Glutamate Receptor 5/1a...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Biology Products: